

PRODUCT INFORMATION




SNDX-5613

Item No. 40758

CAS Registry No.: 2169919-21-3
Formal Name: N-ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl)methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)-benzamide

Synonym: Revumenib
MF: C₃₂H₄₇FN₆O₄S
FW: 630.8
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SNDX-5613 is supplied as a solid. A stock solution may be made by dissolving the SNDX-5613 in the solvent of choice, which should be purged with an inert gas. SNDX-5613 is soluble (≥10 mg/ml) in ethanol and DMSO.

Description

SNDX-5613 is a derivative of VTP-50469 (Item No. 40759), an inhibitor of the protein-protein interaction between menin and mixed-lineage leukemia 1 (MLL1), also known as lysine methyltransferase 2A (KMT2A). It inhibits the growth of patient-derived acute myeloid leukemia (AML) cells expressing the gene encoding upstream binding factor (UBF) and containing tandem duplications (UBF-TDs) when UBF-TD-containing AML cells are co-cultured with mesenchymal stem cells.¹ SNDX-5613 (50 mg/kg) reduces disease burden and improves survival when used alone and, to a greater extent, when used in combination with the CBP and p300 inhibitor GNE-781 (Item No. 36450) in a MOLM-13 mouse xenograft model.² It also reduces disease burden and increases survival in patient-derived xenograft (PDX) mouse models in which tumor cells contain rearrangements in the gene encoding KMT2A or mutations in the gene encoding nucleophosmin 1 (NPM1).³

References

1. Barajas, J.M., Rasouli, M., Umeda, M., *et al.* Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors. *Blood* **143**(7), 619-630 (2024).
2. Fiskus, W., Mill, C.P., Birdwell, C., *et al.* Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. *Blood Cancer J.* **13**(1), 53 (2023).
3. Issa, G.C., Aldoss, I., Dipersio, J., *et al.* The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. *Nature* **615**(7954), 920-924 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/09/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM